1. Stromal lymphocytes are associated with upgrade of B3 breast lesions
- Author
-
Tanjina Kader, Elena Provenzano, Madawa W. Jayawardana, Shona Hendry, Jia-Min Pang, Kenneth Elder, David J. Byrne, Lauren Tjoeka, Helen ML. Frazer, Eloise House, Sureshni I. Jayasinghe, Holly Keane, Anand Murugasu, Neeha Rajan, Islam M. Miligy, Michael Toss, Andrew R. Green, Emad A. Rakha, Stephen B. Fox, G. Bruce Mann, Ian G. Campbell, and Kylie L. Gorringe
- Subjects
Atypical ductal hyperplasia ,Lesions of uncertain malignant potential ,B3 lesions ,Tumour infiltrating lymphocytes ,Stromal lymphocytes ,Upgrade ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Various histopathological, clinical and imaging parameters have been evaluated to identify a subset of women diagnosed with lesions with uncertain malignant potential (B3 or BIRADS 3/4A lesions) who could safely be observed rather than being treated with surgical excision, with little impact on clinical practice. The primary reason for surgery is to rule out an upgrade to either ductal carcinoma in situ or invasive breast cancer, which occurs in up to 30% of patients. We hypothesised that the stromal immune microenvironment could indicate the presence of carcinoma associated with a ductal B3 lesion and that this could be detected in biopsies by counting lymphocytes as a predictive biomarker for upgrade. A higher number of lymphocytes in the surrounding specialised stroma was observed in upgraded ductal and papillary B3 lesions than non-upgraded (p
- Published
- 2024
- Full Text
- View/download PDF